glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Retatrutide vs AOD-9604: Triple Agonist vs Growth Hormone Fragment

Part of Peptides Topic Hub.

Retatrutide vs AOD-9604: Triple Agonist vs Growth Hormone Fragment for Weight Loss

Retatrutide and AOD-9604 have very different evidence bases. Retatrutide is an investigational GLP-1/GIP/glucagon receptor agonist with positive randomized obesity trials. AOD-9604 is a growth-hormone-derived peptide whose largest obesity study did not show a significant weight-loss benefit over placebo. Neither is an FDA-approved weight-loss treatment.

A political announcement or a clinic listing is not evidence of drug approval. This comparison separates clinical results from claims about access.

Side-by-Side Comparison

RetatrutideAOD-9604
TypeGLP-1/GIP/glucagon receptor agonistGrowth-hormone-derived peptide
Obesity evidencePositive Phase 2 and Phase 3 studiesLargest study failed to show benefit over placebo
FDA approvalNot approvedNot approved
Direct comparisonNo head-to-head study identifiedNo head-to-head study identified

How the Mechanisms Differ

Retatrutide: Three Receptors, One Molecule

Retatrutide activates three receptor systems simultaneously:

  • GLP-1 receptor — suppresses appetite through hypothalamic and brainstem signaling, slows gastric emptying
  • GIP receptor — enhances insulin secretion and may improve fat metabolism
  • Glucagon receptor — increases energy expenditure through thermogenesis and promotes hepatic fat oxidation
Glucagon receptor activation is being studied for effects on energy expenditure and hepatic fat metabolism. Preclinical studies support this rationale, but the human trials do not isolate how much weight loss each receptor contributes. Counting receptor targets cannot establish which drug is better. Read how retatrutide works for the mechanism and its evidence limits.

AOD-9604: Targeted Fat Metabolism

AOD-9604 is a synthetic 16-amino acid peptide derived from the C-terminal region of human growth hormone (amino acids 176-191). It was designed to isolate the fat-burning effects of growth hormone without the broader hormonal side effects.

Animal studies examined effects on lipid metabolism. Those findings do not establish a useful fat-loss effect, selective fat targeting, or absence of hormonal effects in humans.

Why This Matters

The practical distinction is evidence: a proposed mechanism cannot substitute for a demonstrated clinical benefit.

Weight Loss Data

Retatrutide Clinical Results

Swipe sideways to see every column.

TrialPhaseParticipantsDurationMax Weight Loss
TRIUMPH-4Phase 344568 weeks-28.7% (12 mg dose)
Phase 2 (NEJM)Phase 233848 weeks-24.2% (12 mg dose)

These are results from different retatrutide studies. TRIUMPH-4 used an efficacy estimand in adults with overweight or obesity and knee osteoarthritis without diabetes; they are not expected outcomes for everyone.

AOD-9604 Clinical Results

The FDA review describes OPTIONS as a 24-week oral study with 536 enrolled and 502 randomized participants. It did not find a significant weight-loss difference at the 12-week primary endpoint. The company ended obesity development in 2007. Earlier summaries lacked enough methodological detail to establish a reliable benefit, and FDA found no human subcutaneous efficacy data.

The Evidence Gap

Positive retatrutide trials do not make it an approved treatment; failed AOD-9604 efficacy does not make that peptide harmless. Comparing unrelated studies cannot establish a personal outcome or a safe combination.

Safety Comparison

FDA flags AOD-9604 for potential immunogenicity and peptide-impurity concerns, limited safety information, and serious adverse-event reports whose causal relationship is unclear. Food-use GRAS claims do not amount to approval of an injectable obesity medicine. Lack of weight-loss efficacy is not evidence that a substance cannot cause harm.
Dysesthesia (altered skin sensation) occurred in 8.8% and 20.9% of the retatrutide 9 mg and 12 mg groups in TRIUMPH-4. It is not unique to retatrutide: current Wegovy and Zepbound labels also report it. A glucagon-specific cause has not been established. See retatrutide safety for the trial context.

Regulatory and Access Comparison

Neither drug has an FDA-approved obesity label or an approved retail price. Lilly plans a US biologics license application in the first quarter of 2027. That is a filing target, not an FDA approval or launch date.
The FDA compounding safety page currently lists AOD-9604 under substances nominated but withdrawn. A nomination category is not drug approval or a blanket permission to compound. This page does not establish a lawful prescribing pathway from an anticipated reclassification. See peptide regulation for the broader context.

Can You Combine AOD-9604 With Retatrutide?

Some clinics and online communities discuss "stacking" AOD-9604 with GLP-1 drugs for a combined fat metabolism and appetite suppression approach. There is a theoretical rationale — they target completely different pathways — but no clinical trial has studied this combination.

The risks of combining them include:

  • No safety data exists for the combination
  • AOD-9604's own efficacy data is weak
  • Adding an unproven compound to a potent drug introduces unknown variables
  • Retatrutide is not available outside of clinical trials, so anyone combining them is using gray market products

Frequently Asked Questions

Is AOD-9604 better than retatrutide for weight loss?

There is no direct trial. Retatrutide has positive randomized obesity results; AOD-9604 has not established comparable clinical efficacy. Neither is an FDA-approved weight-loss prescription.

Clinic and social-media marketing can keep a peptide visible even when clinical efficacy is unproven. Popularity, testimonials, and claims about selective fat loss are not evidence of benefit or safety.

It is not an FDA-approved drug. The FDA page lists its withdrawn nomination and safety concerns. Do not interpret a political announcement, nomination category, or seller availability as a complete answer about lawful compounding.

Does AOD-9604 work for fat loss?

Its largest obesity trial did not establish benefit over placebo. The proposed mechanism and animal findings do not overcome that clinical evidence gap.

Can you take AOD-9604 while waiting for retatrutide?

This is a question for your healthcare provider. AOD-9604 targets a completely different mechanism than GLP-1 drugs and would not provide comparable weight loss results. If you are looking for weight loss medication while waiting for retatrutide, FDA-approved GLP-1 drugs like tirzepatide (Zepbound) or semaglutide (Wegovy) have far stronger evidence. See current GLP-1 pricing.

What is the difference between AOD-9604 and GLP-1 drugs?

They are different molecules and research programs. GLP-1 receptor agonists act through an identified incretin receptor, and several have approved indications supported by large trials. AOD-9604 is derived from growth hormone and has not established efficacy as an obesity treatment.

Sources

  • FDA. AOD-9604 evidence assessment, December 2024.
  • FDA. Compounding safety concerns.

  • Jørgensen, J.O.L., et al. (2004). Phase 2b trial of oral AOD-9604 in obese subjects. Metabolic Pharmaceuticals press release, December 2004.

  • Metabolic Pharmaceuticals. (2007). OPTIONS Study results. The Age, Feb 21, 2007.
  • Stier, H., Vos, E., Kenley, D. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. J Endocrinol Metab. 3(1-2):7-15.
  • Heffernan, M.A., et al. (2001). Effects of hGH and AOD9604 on lipid metabolism in obese mice. Endocrinology. PMID: 11713213.
  • Jastreboff, A.M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972.
  • Eli Lilly. (2025). TRIUMPH-4 results. Press release.
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all peptides topics →